Home » Health » Obesity drug Saxenda 1-week continuous development, patent application

Obesity drug Saxenda 1-week continuous development, patent application

Peptron (CEO Ho-il Choi) announced on the 18th that it developed an injectable obesity treatment saxenda as a 1-week long-acting formulation and applied for a related technology patent.

According to Peptron, the Saxenda Saxenda long-acting formulation uses a drug delivery technology developed in-house to improve the ease of administration from daily injection to once a week. At the same time, it is expected that side effects such as nausea and vomiting can be reduced by reducing the variation in drug concentration immediately before and after injection.

According to the company, long-acting drugs developed by improving the formulation while maintaining the ingredients of the drugs on the market do not have the risk of failure due to toxicity, and the persistence of the drug can be confirmed only by animal testing. Saxenda’s material patent is in 2022.

Copyright © Medical Tribune Unauthorized reproduction and redistribution prohibited

– .

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.